Business
Marina Biotech Announces Evaluation and Option Agreement to Deliver a Genome Editing Technology
Marina Biotech Announces Evaluation and Option Agreement to Deliver a Genome Editing Technology.
About this update from Adhera Therapeutics Inc.
[{"type":"text","content":"\n \n \n Marina Biotech Announces Evaluation and Option Agreement to Deliver a Genome Editing Technology\n \n \nMarina Biotech Announces Evaluation and Option Agreement to Deliver a Genome Editing Technology\n \n BOTHELL, WA--(Marketwired - Feb 18, 2016) - Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases announced today that they have entered into an evaluation and option agreement regarding the Company's SMARTICLES platform for the delivery of an undisclosed genome editing technology. The agreement is notable in that it contains an option provision for the exclusive license of the Company's SMARTICLES platform in a specific gene editing field. This represents the first time that the Company's SMARTICLES technology has been evaluated in connection with gene editing. Further terms of the Agreement were not disclosed.\n \"SMARTICLES continues to be the most widely licensed delivery technology in the nucleic acid therapeutics sector,\" stated J. Michael French, president and CEO of Marina Biotech. \"We are now beginning to see expansion in other therapeutic areas such as gene editing. We hope that the unique properties of SMARTICLES opens novel therapeutic opportunities for patients with unmet needs.\"\n About SMARTICLES Clinical Experience\n Clinical achievements with SMARTICLES represent the combined experiences (a total of approximately 130 patients) of licensees ProNAi Therapeutics, Inc. (NASDAQ: DNAI) and Mirna Therapeutics, Inc. (NASDAQ: MIRN). \n ProNAi's lead product candidate, PNT2258, is designed to target cancers that overexpress BCL2. ProNAi is actively enrolling patients in \"Wolverine\", a Phase 2 trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and in \"Brighton\", a Phase 2 trial evaluating PNT2258 for the treatment of Richter's transformation. For more information, please visit www.pronai.com.\n Mirna's lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34), is currently being studied in a Phase 1 clinical trial in patients with primary liver cancer, advanced solid tumors and hematological malignancies. Mirna plans to develop MRX34 as a monotherapy and in combination with other therapeutic modalities, such as targeted therapies and immuno-oncology agen...